Our Beginning

/ /

OUR BEGINNING

ABOUT US

The Management Team
Our Vision
Our Mission
Our Strategy
Our Beginning
Our Commitment
Our Location

MSD first established its presence in Malaysia in 1965. It started off by distributing products throughout Malaysia, with a staff strength of five employees. In 1978, MSD licensed its business to a distributor, forming a division within the distributor’s business group. In 1993 MSD was established in Singapore, with MSD Singapore taking over the Sales and Marketing function from the distributor the following year.

In December 1997, MSD in Malaysia was established. It functions as an independent entity and is the subsidiary of Merck & Co. of the United States. Today, MSD in Malaysia has more than 300 staff working hand in hand to bring out the best in medicines for Malaysians.

In November 2009, MSD and Schering-Plough merged to form one company. We are now a stronger, more diverse global organization. This not only benefits our company, but it also benefits the millions of people around the world who rely on our products and expect us to continue to deliver exceptional value. MSD is now a leader in a broad range of areas, including cardiology, infectious diseases, diabetes, respiratory, vaccines, women's health, sun care and animal health, and we are also expanding our offerings in other areas, such as neurology, oncology and dermatology.

Forward-Looking Statement

Forward-Looking Statement of MSD & Co., Inc., Kenilworth, NJ, USA

This website of MSD & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.